Risk of dilution of share value due to stock acquisition rights
First written in FY2017. 7 of 13 entries say "Mitigated", first in FY2019-Q1. Latest entry: FY2025.
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
52 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「Exercise 340,600 — Lapsed — — Unexercised balance 21,200 —」
The remaining 21,200 shares underlying the Sixth Series Stock Acquisition Rights were also exercised, eliminating the unexercised balance and reducing the potential dilution. - FY2024MitigatedAnnual report
「Exercise 340,600 — Lapsed — — Unexercised balance 21,200 —」
Exercises of the Sixth Series Stock Acquisition Rights covered 340,600 shares, reducing the unexercised balance to 21,200 shares at the fiscal year-end. The potential dilution has declined from 670,900 shares in the previous fiscal year. - FY2023WorsenedAnnual report
「Number of shares underlying stock acquisition rights (shares) 670,900」
New paid stock acquisition rights were issued immediately before the filing date, creating potential dilution of 670,900 shares. - FY2022RestatedAnnual report
「Stock acquisition rights approved by the Board of Directors on 14 April 2021 Number of stock acquisition rights: 7,440 Common shares: 744,000」
The disclosure reiterates that 744,000 shares underlying the Sixth Series Stock Acquisition Rights remain outstanding. No increase in shares resulting from the exercise of stock acquisition rights had occurred as of the fiscal year-end. - FY2022-Q1WorsenedAnnual report
「Number of shares underlying stock acquisition rights (shares) (Note 2) 744,000」
The number of shares underlying the stock acquisition rights issued during the first quarter was 744,000, creating a new potential for dilution of equity value. - FY2021-Q1MitigatedAnnual report
「② Status of Other Stock Acquisition Rights, etc. Not applicable.」
The current quarterly report states that no other stock acquisition rights, etc. were applicable, and the balance of stock acquisition rights on the balance sheet was 0. Disclosure concerning potential dilution was reduced from the previous report. - FY2020-Q3MitigatedAnnual report
「Fourth Series of Stock Acquisition Rights Number of stock acquisition rights: 5,290 Number of common shares: 529,000 Fifth Series of Stock Acquisition Rights Number of stock acquisition rights: 3,360 Number of common shares: 336,000」
The number of common shares underlying the Fourth Series of Stock Acquisition Rights was 529,000, down from the 535,000 reported in the previous disclosure. The number of common shares underlying the Fifth Series of Stock Acquisition Rights was 336,000. - FY2020-Q1WorsenedAnnual report
「Class and number of shares underlying stock acquisition rights 100 common shares of the Company (total number of shares underlying stock acquisition rights: 336,000)」
Paid stock options were granted on 18 June 2019 after the end of the fiscal year, creating new potential for dilution involving 336,000 potential underlying shares. - FY2019MitigatedAnnual report
「The disclosure covers the Company's own stock options outstanding during the current consolidated fiscal year, which ended in February 2019, and presents the number of own stock options after converting them into the equivalent number of shares.」
The 535,000 shares underlying the Fourth Series of Stock Acquisition Rights expired, and no stock acquisition rights remained at the end of the current consolidated fiscal year, eliminating the potential for dilution from potential shares. - FY2019-Q2MitigatedAnnual report
「Fourth Series of Stock Acquisition Rights Number of stock acquisition rights: 5,290 Number of common shares: 529,000」
The number of common shares underlying the Fourth Series of Stock Acquisition Rights was 529,000, down from 535,000 reported at the end of the previous quarter. Quarterly net income per share after adjustment for potential shares was not disclosed for the cumulative second-quarter period because there were no potential shares with a dilutive effect. - FY2019-Q1MitigatedAnnual report
「Fourth Series of Stock Acquisition Rights Number of stock acquisition rights: 5,350 Number of common shares: 535,000」
The number of common shares underlying the Fourth Series of Stock Acquisition Rights was disclosed as 535,000, down from the 725,000 potential shares reported at the end of the previous consolidated fiscal year. Diluted earnings per share for the first quarter was not disclosed because there were no potential shares with a dilutive effect. - FY2018WorsenedAnnual report
「As of the end of February 2018, the total number of potential shares from stock acquisition rights was 725,000, equivalent to 5.9% of the total number of issued shares if all of these stock acquisition rights were exercised.」
The total number of potential shares increased from 554,000, or 4.7%, in the previous fiscal year to 725,000, or 5.9%, increasing the potential for dilution. - FY2017First statedAnnual report
「As of the end of February 2017, the total number of potential shares from stock acquisition rights was 554,000, equivalent to 4.7% of the total number of issued shares if all of these stock acquisition rights were exercised.」
The disclosure describes the possibility that exercise of stock acquisition rights could dilute future equity value and affect share-price formation.